Analysis of microRNA biomarkers as predictive values for cervical cancer treatment, in relationship with environmental exposure to arsenic, phthalates and ETS

CervicallArsenArray

Cervicall-arsen-array is an inter and multidisciplinary research project under the requirements of the program PN-II-PT-PCCA-2011-3. The activities under this project will be conducted during a period of 48 months.

The project is classified under the 4th. HEALTH, thematic area 4.1.3 Methods of investigation and intervention based on molecular and cellular medicine, genomics and proteomics. The research domain is cervical cancer and the project is aiming to identify new molecular targets to evaluate the treatment efficiency of advanced stages (IIB-IIIB) of cervical cancer by combining the noncoding RNA (miRNA) functional genomic data with toxic exposure (arsenic, phthalates and cotinine).

The main goal of the project is to elaborate a prediction model for therapy response (pharmacogenomics) of patients with advanced cervical cancer (stage IIB-IIIB) based on tissue and serum genomic signature (miRNA-microarray) and to investigate if toxic exposure to the mixture (arsenic, phthalates and cotinine as an ETS biomarker) could influence the treatment response.

Starting / Ending Date

02.07.2012 – 05.12.2016

Project Coordinator

The Oncology Institute „Prof Dr. Ion Chiricuta” Cluj-Napoca – Romania

Funding

Funder: Executive Unit for financing education Higher, research Development and innovation (UEFISCDI)
Grant Number: 96/2012
Total Amount: 3.000.000 RON

Staff from Department of Public Health

Project Partners

The University of Medicine and Pharmacy Cluj-Napoca (UMFCN)
Environmental Health Center Cluj-Napoca (CMS)
Babes Bolyai University Cluj-Napoca (UBB)

Project Outputs

O Tudoran, O Balacescu, I. Berindan–‐Neagoe I., Molecular Pathways Of Angiogenesis In Cervical Cancer. Molecular Pathways of Angiogenesis in Cervical Cancer (pp. 311-326) In Angiogenesis: insights from a systematic overview; Ed. Santulli G., Nova Science Publishers, 2013.
www.novapublishers.com/catalog/product_info.php?products_id=39794

Tudoran OM, Soritau O, Balacescu L, Pop L, Meurice G, Visan S, Lindberg S, Eniu A, Langel U, Balacescu O, Berindan-Neagoe I. PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation. J Cell Mol Med. 2015 Feb;19(2):371-82. (ISI)

Balacescu O, Balacescu L, Tudoran O, Todor N, Rus M, Buiga R, Susman S, Fetica B, Pop L, Maja L, Visan S, Ordeanu C, Berindan-Neagoe I, Nagy V. Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. BMC Cancer. 2014 Apr 8;14:246. (ISI)

Neamtiu I, Dumitrascu I, Roba C. Chemical Analysis of Urinary Cotinine in Subjects Exposed to A Mixture of Contaminants. Indian Journal of Applied Research. 2014 (3). 56-58 (BDI).

Neamtiu I, Dumitrascu I, Roba C. Exposure to Arsenic and Environmental Tobacco Smoke in A Hospitalized Population Group Diagnosed with Cervical Cancer -Preliminary Results From A Pilot Study. IJSR. 2014, 3(3); 71-73 (BDI).

Neamtiu IA, Bloom MS, Dumitrascu I, Roba CA, Pop C, Ordeanu C, Balacescu O, Gurzau ES. Impact of exposure to tobacco smoke, arsenic, and phthalates on locally advanced cervical cancer treatment-preliminary results. PeerJ. 2016 Sep 8;4:e2448. doi: 10.7717/peerj.2448.